alendronate has been researched along with Cushing Syndrome in 3 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Cushing Syndrome: A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption." | 6.69 | Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. ( Colao, A; Di Somma, C; Faggiano, A; Klain, M; Lombardi, G; Merola, B; Pivonello, R; Salvatore, M; Tripodi, FS, 1998) |
| " Followed by hydration with saline, pamidronate is effective for the control of symptomatic hypercalcemia." | 4.79 | [Paraneoplastic syndrome]. ( Hara, N; Nakanishi, Y; Takayama, K, 1997) |
| "Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption." | 2.69 | Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. ( Colao, A; Di Somma, C; Faggiano, A; Klain, M; Lombardi, G; Merola, B; Pivonello, R; Salvatore, M; Tripodi, FS, 1998) |
| "Osteoporosis is a common complication of Cushing's disease/syndrome." | 2.41 | Osteoporotic fractures at presentation of Cushing's disease: two case reports and a literature review. ( Crouzet, J; Fournier, JJ; Khanine, V; Luton, JP; Requeda, E; Simon, F, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakanishi, Y | 1 |
| Takayama, K | 1 |
| Hara, N | 1 |
| Di Somma, C | 1 |
| Colao, A | 1 |
| Pivonello, R | 1 |
| Klain, M | 1 |
| Faggiano, A | 1 |
| Tripodi, FS | 1 |
| Merola, B | 1 |
| Salvatore, M | 1 |
| Lombardi, G | 1 |
| Khanine, V | 1 |
| Fournier, JJ | 1 |
| Requeda, E | 1 |
| Luton, JP | 1 |
| Simon, F | 1 |
| Crouzet, J | 1 |
2 reviews available for alendronate and Cushing Syndrome
| Article | Year |
|---|---|
[Paraneoplastic syndrome].
Topics: Alendronate; Anticoagulants; Cushing Syndrome; Diagnosis, Differential; Diphosphonates; Disseminated | 1997 |
Osteoporotic fractures at presentation of Cushing's disease: two case reports and a literature review.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone and Bones; Cushing Syndrome; Fractures, Spontaneous | 2000 |
1 trial available for alendronate and Cushing Syndrome
| Article | Year |
|---|---|
Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease.
Topics: Acute Disease; Adult; Alendronate; Antifungal Agents; Biomarkers; Bone Density; Collagen; Collagen T | 1998 |